Reporting owner · CIK 0001681098

McFarlane Neil F.

SEC Form 4 history for the last 180 days across 1 company, 3 transactions and 1 filing.

PRESPresident and CEOZEVRA THERAPEUTICS, INC.
Open-market transaction mix0% buys0 buys · 1 sale

Period: Last 180 days

Trade dates in this period: Oct 10, 2026 – Oct 12, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings1Form 4 records
Buying$00 purchases
Selling$225k1 sale
Net value−$225kBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
McFarlane Neil F. transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
ZVRAZEVRA THERAPEUTICS, INC.
President
PRES
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
ZVRAZEVRA THERAPEUTICS, INC.
President
PRES
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$225kView disclosure →
ZVRAZEVRA THERAPEUTICS, INC.
President
PRES
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
—View disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a sale at ZEVRA THERAPEUTICS, INC. on Oct 12, 2026 valued at $224,948.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Monthly open-market activity

Last 1 reported month · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Oct 202601$0$224,948−$224,948

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$225k
Median P/S size$225k
Direct3
Indirect0
Oct 12, 2026sale

Associated companies

Counts cover all available history, including outside the summary period

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in the last 180 days

A 90-day purchase return requires an open-market buy. None is recorded in the last 180 days. Purchases filed earlier are outside the visible history and are not included.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

2 observations · Oct 10, 2026 – Oct 12, 2026. Window ends at the latest available report, not today.

Selected observation · Oct 12, 2026417,225 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Oct 10, 2026437,225Oct 13, 2026View transaction
Oct 12, 2026417,225Oct 13, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

McFarlane Neil F. Insider Activity FAQ

SEC Form 4 context

Who is McFarlane Neil F.?

McFarlane Neil F. is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001681098.

Which companies has McFarlane Neil F. reported transactions for?

ZEVRA THERAPEUTICS, INC.

When was McFarlane Neil F.'s latest insider buy?

No open-market insider purchase is recorded in the last 180 days. Earlier filings are outside the visible history.

When was McFarlane Neil F.'s latest insider sale?

The insider reported a sale at ZEVRA THERAPEUTICS, INC. on Oct 12, 2026 valued at $224,948.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.